Cdk5 Phosphorylates Dopamine D2 Receptor ma Attenuates Downstream Signaling (2013)

Faʻamatalaga: Faʻaalia e faʻaalia ai o le Cdk5 e mafua ai le faʻatonutonuina o le dopamine D2 receptors. O le mea e ofo ai, o le fa'aliliuga o le deltafosb e fa'aosofia ai le gaosiga o le Cdk5.


Jeong J, Park YU, Kim DK, Lee S, Kwak Y, et al. (2013) PLOS ONE 8 (12): e84482. doi: 10.1371 / journal.pone.0084482

lē faʻatino

O le dopamine D2 receptor (DRD2) o se faʻamaufaʻailoga autu e faʻasalalau galuega faiʻai e fesoʻotaʻi ma le dopamine e pei o lagona, taui, ma lagona. Cyclin-faalagolago kinase 5 (Cdk5) o se proline-directed serine / threonine kinase o lana galuega na aʻafia i le vaʻaia o taui o le faiʻai. I lenei suʻesuʻega, na matou faʻaalia ai o le serine 321 toega (S321) i le tolu intracellular loop o DRD2 (D2i3) o se nofoaga faʻatonutonu fou a Cdk5. Cdk5-faalagolago phosphorylation o S321 i le D2i3 sa matauina i i vitro ma faiga masani faaleaganuu.

Na matou maitauina foi o le fugaina o le S321 na faaleagaina ai le faʻaalia o foliga o DRD2 ma faʻaitiitia le fugatini G i le DRD2. E le gata i lea, o le auala i lalo o le CAMP na aʻafia i le faʻaaogaina o le faʻaaogaina o le tino ma i totonu o aganuu muamua mai le p35 knockout embryos atonu e mafua mai i le faʻaitiitia o le faʻasaina o DRD2. O nei taunuuga e faailoa ai o le Cdk5-faʻasalalau phosphorylation o le S321 faʻalavelaveina le DRD2 galuega, ma tuʻuina atu ai se faiga faʻavae faatonutonu mo le faailoina o dopamine.

Fuainumera

Fuaiupu: Jeong J, Park YU, Kim DK, Lee S, Kwak Y, et al. (2013) Cdk5 Phosphorylates Dopamine D2 Receptor ma Attenuates Downstream Signaling. PLOS ONE 8 (12): e84482. doi: 10.1371 / journal.pone.0084482

Faatonutonu: James Porter, Iunivesite o North Dakota, Iunaite Setete o Amerika

Maua: Me 20, 2013; Talia: Novema 14, 2013; Lomia: Tesema 31, 2013

Puletaofia: © 2013 Jeong et al. O se faʻasalalauga avanoa lea e tufatufa atu i lalo o tuutuuga o le Laisene Creative Commons Attribution, lea e faatagaina ai le le faʻaaogaina o le faʻaaogaina, tufatufaina atu, ma le toe gaosia i soʻo se auala, pe'ā tuʻuina atu le tusitala muamua ma le punaʻoa.

Faatupeina: O lenei galuega na lagolagoina e le polokalama NRF-2012R1A2A2A01012923 ma le NRF-2012R1A4A1028200 mai le malo Korea (MSIP) ma lagolagoina foi i lalo o le faʻavae o le galulue faʻatasi faavaomalo na pulea e le NRF o Korea (2012K2A1A2033117) ma le Korea Brain Research Institute (KBRI) Polokalame Muamua Suesuega a le MSIP (2031-415). O le SKP na mauaina le 2004 ma 2006 National Alliance mo Suʻesuʻega Schizophrenia ma le Faʻavaivai (NARSAD) Awards a le Au Talavou Suesuega. E leai se sao o le au fai tupe i le faia o suʻesuʻega, o le aoina o faʻamaumauga ma le auʻiliʻiliga, filifiliga e lolomiina, poʻo le saunia o tusitusiga.

Tauvaga malie: Ua faailoa mai e tusitala e leai ni aia tauva.

faʻatomuaga

O le faailoga o le Dopamine e aafia i galuega eseese a le faiʻai e aofia ai le faʻatautaia o masini, faʻaleleia o lagona ma taui [1]. O se vaega tele o le dopamine o le faailogaina i vertebrates o loʻo faʻaaogaina e ala i le telefoni e faʻaogaina ai le telefoni (MSNs) lea e faʻaalia ai se vaega o le suʻega o le dopamine ma maua ai saofaga dopaminergic mai le vaega faʻalauteleina (VTA) ma le televala (SN) [2]. O le faʻaaogaina o le Dopamine o G-protein-receptors receptors (GPCR) faʻatasi ma le numera fitu o le transmembrane ma e aofia ai le lua subtypes, D1-pei ma D2-pei o le talitutusa, lea e vavalalata i taga faʻafaʻatasi i le faailo o dopamine [1]. Mo se faʻataʻitaʻiga, o loʻo faʻaauau le tali a le dopamine D1-like receptors (D1, D5) i le adenylyl cyclase e ala ile Gαs ma faateleina le maualuga o le intracellular o le CAMP, ae o le dopamine D2-pei o le talitutusa (D2, D3, D4) e taofia ai le adenylyl cyclase e ala ile Gαi ma faaitiitia le tulaga intracellular o le CAMP [1], [3].

Faatasi ai ma le responsors dopamine, o le D2 receptor (DRD2) e aafia i le pathophiosiology o le tele o le mafaufau tele o le mafaufau e aofia ai le schizophrenia ma le tagofia o fualaau faasaina [4], e pei o le tele o antipsychotic fualaau faʻataʻitaʻi e le itiiti ifo i le vaega faʻataʻitaʻI DRD2. O loʻo iloa foʻi o le DRD2 faʻamalosia lelei le amio lelei o fualaau faʻasaina i faʻataʻitaʻiga manu [5]. O aʻafiaga faʻamalolo ma le faʻafouina o le faʻaleleia o le faʻalavelave ua fesoʻotaʻi atu foi i suiga i le faʻaaliga o foliga o le DRD2 poʻo le faʻamaoniga o intracellular i lalo ole paka, ERK ma le GSK3 [1], [4], [6]. E ui lava i nei matafaioi taua mo le DRD2 i le faiʻai, o le auiliiliga o tulafono faatonutonu e tuʻuina atu ai le faʻaauau ma le faigata i DRD2 meatotino e le o malamalama atoatoa.

O le liuaina o laina o faʻamaoniga e faʻaalia ai le tele o suiga i tua o loʻo aofia ai i le faʻaleleia lelei o le DRD2. Na faʻaalia le faʻataʻitaʻiina o le DRD2 i le vave amataina o le faʻataʻitaʻiina o suʻesuʻega [7], ma faʻaleagaina le faʻavaeina o faʻatagaga i totonu DRD2 na faʻaalia foi o se suiga taua mo le fusia o liga [8]. E le gata i lea, o nofoaga o le phosphorylation o DRD2 na muaʻi faailoaina e i vitro faʻataʻitaʻiga i le radioisotopes, tuʻuina atu auala mo auala eseese faatonutonu faʻasalalau e ituaiga eseese [9]. E moni, o le protein kinase C (PKC) e faʻatautaia le DRD2-faʻasalalauga faʻasalalauga o le calcium intracellular ma faʻaleleia le fegalegaleaiga a DRD2 ma aʻafiaga cytoskeletal [10]. Faʻapipiʻiina e le GPCR kinase 2 (GRK2) e faʻatautaia ai mamanu o le toe faʻafouina o le DRD2 [11].

5 (Cdk5) o le Cyclin-dependent-o se faʻasolosolo faʻasolosolo / threonine kinase faʻasolosolo ona o le faʻataʻitaʻiga o le mafaufau o ona tagata faʻaleleia, p35 ma le p39 [12]. Cdk5 o loʻo aʻafia i le tele o gaioiga o le neuronal e aofia ai le faʻavaveina o femalagaʻiga ma le taʻitaʻiga, ma le Cdk5 ma le p35 null mice e faʻaalia ai ni faaletonu i le taotoga [13]. Talu ai nei, na faaalia ai o le faʻamalosia o le WAVE1 ma le ephexin e le Cdk5 e faʻafoe ai le dendritic spinal morphogenesis [14]. E le gata i lea, o Cdk5 foi e faatonutonuina tulaga o faʻaaliga o le maualuga o le nusiva NMDA, NR2B, ma NR2A-faʻafefeteina NMDA [15], [16]. E maitauina o le tele o faʻamatalaga e faʻamaonia ai se mafutaga vavalalata i le va ole Cdk5 ma le polokalama dopamine. Cdk5 phosphorylates tyrosine hydroxylase (TH), faʻatonutonuina lona tulaga mautu, ma tausia ai le homeostasis dopaminergic [17]. I vailaʻau postsynaptic, pe a faʻatulagaina le T75 o le dopamine ma le cyclic-AMP phosphoprotein-32kD (DARPP-32) i le Cdk5, e mafai ona taofia le PKA ma faʻaalia le antagonize dopamine DRD1-mediated PKA signaling [18]. O le mea e mataʻina ai, pe a fai o le cocaine, o se tagata e le faʻasalalauina o le resamine o le dopamine, e faʻasolosolo taimi i kioti, mRNA ma le palatini o le Cdk5 faʻateleina i le vavao vaʻai [19]. I le tuufaatasiga, o Cdk5 e foliga mai o loʻo aʻafia i faʻatautaia synaptic faʻataʻitaʻiina. I lenei suʻesuʻega, matou te faʻaalia se fegalegaleaiga lelei o DRD2 ma Cdk5 lea e faalautele atili ai le matafaioi o le Cdk5 i le signamine signaling.

Mea ma Metotia

Togafitiga

O serums a le rabbiti na totoina e faasaga i peptides o loo i ai le phospho-serine 321 (pS321) o le tolu o intracellular loop DRD2 (D2i3). Phospho-peptide, CNPDpSPAKPEK (PEPTRON), na faʻaaogaina e faia ai se koluma faʻasolosolo peptide-faʻamalosi mo le faʻamaina o le tino (20401, PIERCE). O le anti-pS321 antibody na faʻamalosia e se faiga faʻapitoa faʻamalosia e mulimuli i le faʻatonuga a le kamupanī. O phospho-faʻamaʻi faʻamalosi na teuina i PBS ma 0.1% sodium azide ma 0.1% gelatin. O le antibody-Anti-sourit anti-Cdk5 antibody (sc-249) ma anti-rabbit anti-p35 antibody (sc-820) na faʻaaoga mo le Western blotting ma le immunocytochemistry o Cdk5 / p35. Aneti-anti-GFP antibody (sc-9996) na faʻaaogaina mo le puipuia ma le faʻaaogaina o Western DRD2-GFP. O le antibody (ant-rabbit anti-FLAG antibody) (sc-807), anti-rabbit anti-HA antibody (sc-805), anti-souruse anti-GST antibody (sc-138), ma anti-souruse anti-GAPDH antibody (sc- 32293) na faʻatau mai Santa Cruz Biotechnologies.

manu

O le p35 knockout mouse o se meaalofa alofa mai Dr. Katsuhiko Mikoshiba i le RIKEN Brain Science Institute i Iapani ma sa faʻaogaina mo le aganuu muamua. Polokalame muamua mo le keneraina o 5'- GGTCTCCTCTTCTGTCAAGAAG, 5'-GCTCTGCTAGACACATACTGTAC ma 5'- TCCATCT GCACGAGACTAGT e pei ona faʻamatalaina muamua [20]. ICR ma ma Sprague Dawts kiore na faʻaaogaina mo sauniuniga o le faiai o lili. O faʻataʻitaʻiga uma o manu na faʻatagaina e le Pohang University of Science and Technology Corporation Faʻavae ma le Faʻaaogaina o Manu.

Faʻamatalaga Palasia

Fomaʻi DRD2 umi i le vevela o le plasmid EGFP-N1 ma le tolu o le intracellular loop of DRD2 (212-373 amino acids e aofia ai le 29 faʻaopoopoga amino acids i le DRD2 long isoform) i se vete plasmid pFLAG-CMV-2. Na faʻapipiʻi le Cdk5 tagata i se velas plasmid pCMV-HA ma le p35 tagata na faʻaofi i totonu o se velas plasmid pcDNA 3.1. O Cdk5 tagata na faʻapipiʻiina i lalo o le promoter cytomegalovirus (CMV) faʻatasi ai ma le p35 tagata ile pcDNA 3.1 vevela e fai ai se fausaga e lua (constructing) expression (Cdk5 / p35) mo le immunocytochemistry, fofo international assay, [35S] -GTPγS o le tui faʻamalosi, faʻamalosia o le radioligand assay ma le mimamassay i le CAMP.

I Vitro Faʻasalaga Lelei

IP-fesoʻotaʻi i vitro tau o le kinase sa faia e pei o le mulimuli. O le tasi o le mouse o le faiʻai sa tuiina i le 3 mL erythrocytes lysis (ELB) (50 mM Tris (pH 8.0), 250 mM NaCl, 5 mM EDTA, 0.1% NP-40) e 20 strokes o se Komiunisa faʻamaonia e maua ai le lysates o le homogene . O le lysates na faʻafefiloi i luga o le aisa mo le 30 min, sonicated, ma centrifuged i le 16,000 × g mo 10 min. O le supernatants na puipuia mai i le anti-p35 antibody mo le mauaina o se Cdk5 / p35 faʻamalosi malosi. Cdk5 / p35 complexes ma faʻamalosia le GST fusion protein na faʻafefiloi ma le adenosine 5'-trifatphate, [γ-32P] (NEG-502H, PerkinElmer) ma faʻaosoina i le paʻi kinase (30 mM HEPES (pH 7.2), 10 mM MgCl2, 0.2 mM DTT) mo le 1 h i le vevela vevela [18], [21]. Na faʻamaonia Cdk5 / p25 complex (14-516, Millipore) mo i vitro kinase oso e pei ona faamatalaina i luga. O le 2 × sample loading box na faaopoopo i le faʻafefetega faʻafefete ma faʻapipiʻi i le 100 ° C. O faʻataʻitaʻiga na tuʻuina atu i le SDS-PAGE ma o le gel malogo na suʻesuʻeina e ala i aʻoaʻoga.

Liquid Chromatography (LC) -Faamilosaga o le Spectrometry (MS) / MS

O le glend-GST-D2i3 protein na suʻeina e LC-MS / MS pe a maeʻa ona faʻaogaina IP i vitro kinase oso. Matou te faia le faʻamatalaga peptide o le LC-MS / MS faʻamatalaga e faʻaaoga ai X !! Tandem (version Dec-01-2008). O faila uma RAW data na muamua liua i le mzXML e faʻaaoga ai le pipeline trans-proteomic (TPP; version 4.3). MS / MS suʻesuʻe i mzXML ua liua na maua i suʻesuʻega faasaga i le komepiuta o le faasologa o le poloka o le komepiuta UniProt (faʻasaʻoina 2010_07) e aofia ai le GST-D2i3 faʻasologa e faʻaaoga ai le X !! Tandem. O le faapalepale na setiina i le 3 Da mo vailaau muamua ma le 2 Da mo ioni fragment. Na faʻaaogaina le Enzyme faapitoa mo le trypsin. O suiga fesuiaiga na faʻaaogaina mo le carbamidomethylation o le cysteine ​​(57.021 Da), o le faʻamaina o le methionine (15.995 Da), le hydrolysis o asparagine (0.987 Da) ma le phosphorylation o le serine (79.966 Da).

Faʻatonuga

Na faia le faʻamalolo i luga o lysates cell i ELB lysis faʻamau. O le anti-GFP antibody na faaopoopoina i lysates ma faʻapipiʻiina mo le 3 h i le 4 ° C. Na faʻamamaina faʻamalositino e faʻaaoga ai le protein-A agarose. O mea na afaina ai na faʻaaogaina i le SDS faataitaiga mo le 30 min i le 37 ° C, ma tuʻuina atu i le SDS-PAGE ma le itu i sisifo.

GST Manulagi lalo

10 μg o le GST ma le GST-D2i3 ua faʻamamaina i le rat lysate rat mo le 1.5 h i le 4 ° C. 30 μL o le glutathione (GSH) -o le faʻasologa o le Sepharose 4B beads (17-0756-01, GE Healthcare) ua faʻamaoniaina ma le faʻamaʻi lysis na faaopoopoina ma faʻapipiʻiina mo 1 i. Na faʻapipiʻi pusi i le centrifugation i le 2,000 ×g ma faʻamamaina faʻatasi ma le faʻamalosi faʻamalosi 4 taimi [22], [23]. O mea na maua mai i le itu i sisifo o loʻo faʻaaogaina anti-Cdk5 ma anti-p35 antibodies.

Immunocytochemistry

O suauu HEK 293 ua suia ma ni neorons e masani ona totoina i luga o ufiufi na mulumulu i le taimi e tasi ma le salini ua gaosia (phosphate saline saline) (PBS) ma faʻamautuina i le faatofu i le malulu 4% paraformaldehyde / PBS mo le 30 min. Na faʻaitiitia le faʻamalosaga a le Peraimeri i le fofo puipui (2% faʻatasi ma solofanua ma 1% Triton X-100 i PBS). O le antibody mo le anti-souris Alexafluor-647 (A20990, Invitrogen) ma le Alexafluor-568-anti-rabbit antibody (A11011, Invitrogen) na faʻaaogaina e avea ma faʻaupuga lona lua. O le Hoechst na faʻaaogaina mo le pipiiina o mea. O ata na maua mai i le microscopy (Olympus, FluoView-1000).

Faʻatonuina le Faʻasalalauga Faʻatino

24 h i le maea ai o le gaogao, na togafitia faʻamaʻi i 1 μM quinpirole (Q102, Sigma) mo 30 min ma 90 min i le 37 ° C. Sa toe faʻaaogaina le siama i le 2 mL o le PBS malulu ma 200 μL aliquots sa faʻaaogaina mo tali taitasi. O togafitiga o vailaau na faia i le vevela o le potu mo le 3 h i vaega nei; 3 nM [3H] -spiperone (NET-565, PerkinElmer), 3 μM sulpiride (895, TOCRIS), 10 μM haloperidol (H1512, Sigma). Laʻau faʻaleagaina [3H] -pipperone na faʻaaogaina e faʻaigoaina ai faʻamatalaga uma na faʻaalia ma faʻaaogaina sulpiride hydrophili na faʻaaogaina e sui ai le siaki o le talipupuni [3H] -pipiperone. O faʻamaumauga o faʻamaumauga e aʻafia i le numera o tagata na fuafuaina e ala i le toesea o taulaʻau o le talipiula intracellular mai le aofaʻiga o faʻamalamalamaga o faʻamaumauga. Sa faʻamamaina sulu i luga o le GF / B (Millipore) ma fufulu taimi 3 faʻatasi ai ma le fufuluina o le pa (50 mM Tris-HCl (pH 7.4), 100 mM NaCl). Na faʻamamaina ma faʻaaogaina le eletise i le faʻaaogaina o le faʻamalosi vai [24].

Sauniuniga o le Cell Cell

Faʻamalamalamaina o sela i le 100 mm-aganuʻu ina ua uma ona fufuluina le gaosiga i le malulu malulu o le PBS ma selesele i le 1 mL HME pa (25 mM HEPES (pH 7.5), 2 mM MgCl2, 1 mM EDTA). Lysates Homogenised na centrifuged ma le 500 × g mo le 15 min ma na mulimuli ane faʻapipiʻiina le supernatants i 36,000 × g mo 30 min. Toe faʻaaogaina pellets i le pa puipui HME na faʻaaogaina mo suʻega.

[35S] -GTPγS Sinding Assay

O vaega ninii o le membrane i le siama sa muaʻi faʻaofiina i le 1 μM quinpirole (Q102, Sigma) i le faʻamalosi (25 mM HEPES (pH 7.5), 1.5 mM MgCl2, 100 mM NaCl, 1 mM EDTA and 0.01 mM GDP) for 10 min. [35S] -GTPγS (NET-030H, PerkinElmer) na faʻaopoopoina i le faʻamoemoe mulimuli o 3 nM i le 30 μL ma faʻaopoopoina ai le 90 min. 170 μL o le malulu malulu (10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM MgCl2, ma le 0.1 mM GTP) na faʻaopoopo e taofi le tali. Na faʻamamaina sui i se fuʻa GF / B (Millipore) ma fufulu taimi 3 faʻatasi ai ma le fufulu mama (50 mM Tris-HCl (pH 7.4), 100 mM NaCl). Ua maeʻa ma faʻaaogaina le eletise i le faʻaaogaina o le scintillation counter [25], [26].

Radioligand Sini Fesoasoani

Na faʻapipiʻiina i le 0.01 nM le faʻataunuʻuina o siama faʻamalosi (3H] -spiperone (NET-565, PerkinElmer) ma le faateleina o le mamafa o quinpirole (Q102, Sigma) mo le 30 min i le mea o loʻo fesoasoani ai (25 mM HEPES (pH 7.5), 1.5 mM MgCl2, 100 mM NaCl, 1 mM EDTA). Na faʻamamaina sui i se fuʻa GF / B (Millipore) ma fufulu taimi 3 faʻatasi ai ma le fufulu mama (50 mM Tris-HCl (pH 7.4), 100 mM NaCl). O le tali na faʻamutaina e ala i le vave faʻamaeʻaina i filiga GF / C. Sa faʻatusatusaina le leitio le tumau e faʻaaoga ai se siaki eletise vai [27]-[29].

CAMP Enzyme Immunoassay

Na maua i le 293 μM rolipram (R10, Sigma) le elemene o le HEK 6520, ona togafitia lea ma le 1 μM forskolin (F0.1, Sigma) ma le faateleina o le tele o quinpirole (Q6886, Sigma) mo 102 min. O taʻavale faʻapitoa a le Peraimeri na togafitia i le 30 μM rolipram mo le 10 h, ona 1 μM dopamine mo 1 h [22]. Lysates o le siama na saunia ma le 0.1 M HCl ma numera o le CAMP na maua e le kita immunoassay enzyme enzyme (Sapphire Bioscience) mulimuli i le faatonuga a le kamupanī.

Peraimeri Faʻatoʻa Faʻatoʻaina Neuron

O le vaega tele na vavae ese mai le faiva o le fomaʻi pepe (E15). O le gasegase o le tino na vavaeeseina i le itiiti o le aufaasālalau talafeagai (MEM) (11095, Invitrogen) o loo aofia ai le 0.25% trypsin (T4549-100, Sigma) ma le 0.1% DNase I mo le 6 min i le 37 ° C. Sa toe faʻamalo le masini i le aufaʻasalalau (MEM ma le 0.01 M HEPES (pH 7.4) ma le 10% (vol / vol) solo o solofanua (16050-122, GIBCO)). Neuron na togafitia mo 7 aso i vitro (DIV 7) i le MEM ma le B27 faaopoopo (17504-044, Invitrogen) aʻo leʻi faʻaaogaina i immunoassays enzyme CAMP.

i'uga

Cdk5 Phosphorylates Serine 321 i le Tolu Intracellular Loop o DRD2 i vitro

Mo le sailia o tusiga Cdk5, sa matou faia se sailiga faʻaaoga e faʻaaoga ai le (S / T) PX (K / H / R) ao faʻatulagaina le maliega a le Cdk5 [30] ma faʻaalia DRD2 o se sui sui. O le maliega autasi, e aofia ai le serine 321, o loʻo i totonu o le tolu intracellular loop of DRD2 (D2i3) lea na faʻalavelave ai faiga faʻavae faatonutonu. [3], [10], [11]. O le faasologa e faʻavasegaina faʻatasi i DRD2 i vertebrates, e faʻaalia ai le taua o le mea totoe (Fig. 1A).

ata vali

Ata 1. Cdk5 phosphorylates serine 321 i le tolu intracellular loop of DRD2 in vitro.

(A) Faʻatulagaga faasologa ole amino acids e faʻaalia ai nofoaga faʻasaoina o DRD2 mai ituaiga eseese (paolo). O le nofoaga o le Cdk5 phosphorylation e mafai ona faʻaalia e se faʻamau. (B) faʻaogaina IP i vitro kinase osofaʻi ma le GST-D2i3 ma le GST-D2i3 mutant proteins. Cdk5 / p35 faʻalavelave faʻamalosia mai i le mailei o le faiʻai o le faiʻai e ala i le anti-p35 immunoprecipitation sa faʻaaogaina mo tali o kinase. O le autoradiograph o proteins phosphorylated o loʻo faʻaalia faatasi ma Coomassie e lanu moana lanumoana o le geli lava e tasi. O le pito i luga o loʻo taʻu mai ai le faʻasalalauga e faʻafeiloaʻi i le GST-D2i3s ma le matala matala o loʻo faʻaalia ai faailo faʻasao mai le p35. (C) Sisifo MS / MS o le vaega peptide phosphorylated o le D2i3. O mamanu o le vaevaega o loʻo faʻaalia i lalo ole fusi. Faatasi ai ma vaega uma o vaega, o le y-and b-ion ua iloa o loo faailoa mai i le fusi o leo. Le y6 ma le y7 ions malosi e taʻu mai ai le phosphorylation o le serine 321. (D) In vitro kinase oso faʻatasi ma le mama Cdk5 / GST-p25 complex using GST-D2i3 and GST-D2i3 mutant proteins. Na faʻaalia i totonu o le autoradiograph ia pulufoni fufulu, faatasi ai ma Coomassie e lanu moana lanumoana. O le pito i luga o loʻo taʻu mai ai le faʻaliliuina o le leitio e tutusa le GST-D2i3 ma le mata uʻamea matala o faʻamaoniga mai le GST-p25.

Pule: 10.1371 / journal.pone.0084482.g001

Ina ia iloilo le gafatia o le Cdk5 i le phosphorylate D2i3, sa matou faia le IP i vitro i le faaaogaina o le Cdk5 / p35 faʻamalosia e faʻaaogaina ai le lysate o le kiota mosaʻo e le p35 immunoprecipitation ma le GST-D2i3 (resine amino acid residues 212-373) e avea ma sui. Na matou matauina faailo o le phosphorylation i le faamamaina o le GST-D2i3 ma le GST-D2i3 S297A, ae na faaitiitia le faailoga e ala i le faaaogaina o le GST-D2i3 S321A (Fig. 1B). Ina ia faʻamaonia atili le phosphorylation o le serine 321 i le GST-D2i3, sa matou faia suʻesuʻega LC-MS / MS o faʻataʻitaʻiga mai le IP i vitro kinase assays e faʻaaoga ai le spectrum spectrum LTQ XL. E tumau pea, o phospho-peptides e tutusa ma le tele o pepides phospho-serine 321 ua toe faaola (Fig. 1C). Mafaufau i le mauaina o faʻamaumauga i le taimi o le LC-MS / MS e faʻaalia ai le tele o aʻafiaga i le faʻataʻitaʻiga [31], o lenei faʻamatalaga e taʻu mai ai o le vailaau 321 o totoe o le nofoaga autu phosphorylation o le Cdk5 i le itū o D2i3. Ina ia faamaonia le saʻo phosphorylation o le serine 321 i le GST-D2i3 e le Cdk5, i vitro kinase oso i le faʻaaogaina o Cdk5 / GST-p25 faʻamamaina faʻatasi ma le faʻamalosi o le GST-D2i3 protein. Na matou faailoaina se faailoilo iloga i le GST-D2i3 na le i ai i le GST-D2i3 S321A (Fig. 1D). I le tuufaatasiga, o nei taunuuga e faailoa ai o le D2i3 S321 o se mea e sili ona lelei mo le Cdk5-mediated phosphorylation.

Cdk5 Phosphorylates Serine 321 i le Tolu Intracellular Loop o DRD2 i Cells

Ina ia iloa le phosphorylation o le serine 321, na matou siitiaina le antibody faapitoa mo le phospho-serine 321 (pS321). Faataʻitaʻiga mai le IP-fesoʻotaʻi i vitro o le kinase assay na suʻeina e ala i le faʻaaogaina o le Western Western e faʻaaoga ai le anti-pS321 antibody. Na faʻaalia e le paluga se kulupu manino i le kinase reaction e faalagolago i le GST-D2i3 (Fig. 2A). Ina ia faʻamaonia le mafai ona maua mai le phosponei o le serine 321 i DRD2 e Cdk5 i sela, faafomaʻi anti-GFP mai i le HEK 293 o loʻo faʻaali DRD2-GFP ma DRD2 S321A-GFP faʻatasi ma le HA-Cdk5 ma le p35 na suʻeina e le Western Western blotting faʻaaoga anti-GFP anti-pS321 antibodies. O faailoilo o faaili o le faaili o le anti-GFP e iloa ona o le tele o le glycosylation o DRD2 e na o le DRD2-GFP lava, ma le anti-pS321 antibody na maua ai DRD2 tutusa na o le Cdk5 / p35 co expression (Fig. 2B) [7]. Mo le faʻamaonia atili o le phosphorylation o le serine 321 e le Cdk5, D2i3 (FLAG-D2i3) ma le ituaiga mutant o le D2i3 (FLAG-D2i3 S321A) sa faia. FLAG-D2i3 ma le FLAG-D2i3 S321A na faʻaalia i le HA-Cdk5 ma le p35 i le HEK 293 o loʻo faʻavasegaina e le SDS-gel mo le suiga o le suiga o le vaalele. O se suiga taua ole Cdk5-faʻalagolago i le gaoioi na vaʻaia mo FLAG-D2i3, ae le mo FLAG-D2i3 S321A (Fig. 2C). Na matou iloiloina foi le maualuga o le phosphorylation o DRD2 i le Ser321 i luga o le faaosoosoga o le agonist. O faʻaaliga HEK 293 e faʻaalia DRD2-GFP ma Cdk5 / p35 faʻalavelave na faʻamalosia e le quinpirole, ma le anti-GFP immunoprecipitates from lysates cell were analyzed e le Western Western blotting faʻaaoga anti-GFP ma anti-pS321 antibodies. Na matou iloa o le Cdk5-faʻasalalau phosphorylation o DRD2 i Ser321 e le afaina i le osofaʻi o le agonist, lea e foliga mai e ese mai le GRK- ma le PKC-mediated phosphorylations (Fig. 2D) [32], [33]. Faʻatasi, o nei faaiʻuga e iloa ai e mafai e le Cdk5 ona faʻapipiʻi le vase 321 o le DRD2 i totonu o le siosiomaga feaveaʻi.

ata vali

Ata 2. Cdk5 phosphorylates serine 321 i le tolu intracellular loop of DRD2 i sela.

O le Cdk5-faʻasalalau phosphorylation o le serine 321 na suʻeina e ala i le faʻaaogaina o le anti-pS321 antibody. (A) Faataʻitaʻiga mai le IP i vitro kinase fofo faʻaaogaina masini GST-D2i3 na suʻeina e le Western Western blotting (WB) faʻamaʻi faʻamaonia. Faʻafanua o loʻo faʻaalia GST-D2i3s. (B) DRD2-GFP ma DRD2 S321A-GFP sa faʻamatalaina i poʻo le leai o HA-Cdk5 ma p35 i le HEK 293. O le puipuia o le anti-GFP i le itu i sisifo o le faaaogaina o anti-GFP ma anti-pS321 antibodies. O le faʻamau e faʻamaoniga ai faailoga DRD2 ma matala matala e faʻaalia ai faʻamaoniga faʻamaonia mai le anti-GFP immunoprecipitates. '% input' o le% numera o le lysate atoa mo se tali IP. O faʻataʻitaʻiga Cdk5 faʻamaoniga na faʻaalia e le asterisks. (C) Faʻaaogaina le suiga o le gaioiga. O le HEK 293 suauu na faʻaaogaina e pei ona faʻaalia na suʻesuʻeina e le Western Western blotting. (D) Na togafitia faʻamaʻilagi o le HEK 293 i faʻamaʻi ma le anti-GFP immunoprecipitates na faʻataʻitaʻiina e le Western Western blotting faʻatasi ai ma anti-GFP ma anti-pS321 antibodies. O le matala matala e faʻaalia ai faʻamaoniga faʻapitoa mai le anti-GFP faʻamaonia.

Pule: 10.1371 / journal.pone.0084482.g002

Cdk5 / p35 Complex ma le DRD2 o Fesootaiga Faʻatasi

Sa matou suʻesuʻeina le fegalegaleaiga faaletino i le va o le Cdk5 / p35 complex DRD2 ona o le tele o substrates Cdk5 e iloa e faʻapitoa i le faaletino ma le Cdk5 / p35 complex [23], [34], [35]. Muamua, na faia le suʻega a le GST. O le masini o le GST-D2i3 toe faʻafouina na faʻamamaina i le rat brain lysate ma le GST na faʻapipiʻiina ai le faʻaaogaina o vaʻaia mo le faʻaogaina o le itu i sisifo. E pei ona faʻaalia i Fig. 3A, o le Cdk5 ma le p35 o loʻo faʻaalia i vaʻavave, o faʻaalia ai se fegalegaleaiga faaletino i le va o DRD2 ma le Cdk5 / p35 complex (Fig. 3A). E le gata i lea, na maua le HA-Cdk5 ma le p35 i le anti-GFP i le puipuiga mai le LKS 293 cell lysates e faailoa DRD2-GFP ma Cdk5 / p35 (Fig. 3B). E le gata i lea, na matou faia suʻesuʻega faʻamautinoaga ma le matauina o DRD2-GFP, HA-Cdk5 ma le p35 o loʻo faʻaalia ai faʻamaufaʻailoga o le co-localization i le vaega o le HEK 293 (Fig. 3C, pito i luga o paneta). Na matou suʻesuʻeina foi le faʻatasi o le DRD2 ma le Cdk5 / p35 i le faʻaoga o le neuronal. O le taimi nei, na faʻaalia ai DRD2-GFP le faʻaogaina o le co-localization faʻatasi ai ma le Cdk5 ma le p35 i vailaʻau faʻatoʻaga (DIV7), ma lagolagoina atili ai fesoʻotaiga i le va o DRD2 ma Cdk5 / p35 (Fig. 3C, pito i lalo). O iʻuga e taʻu mai ai DRD2 ma Cdk5 / p35 e mafai ona fausiaina se mea faigata ma o lea, lagolagoina le manatu o DRD2 o se mea faʻapitoa o le Cdk5.

ata vali

Ata 3. Cdk5 / p35 e mafai ona fausiaina se faʻalavelave ma DRD2.

(A) Suʻega o le GST i le faʻaaogaina o le palatini GST-D2i3 toe faʻamalosi mamaina e maua mai ai le iʻai o le lolo. GST i lalo ifo o le gataifale na maua i lalo o iloiloga a le Western Western filtting. 'Bead' o loʻo faʻaalia ai le toso ese mai fafo e aunoa ma le puipuiga o le GST. (B) Puipuiga ole DRD2 male Cdk5 / p35. O le IP-Anti-GFP IP mai lysates mai suauu ua toe faʻaaogaina na tuʻuina atu i suesuega a le Western Western blotting. O le faʻamau e faʻamaoniga ai faailoga DRD2 ma matala matala e faʻaalia ai faʻamaoniga faʻamaonia mai le anti-GFP immunoprecipitates. O le fufuluina o le poloka mo mea e faatino ai mea o loʻo faʻaalia i le taumatau. (C) Iloiloga o le Immunocytomical Chemicals o DRD2 ma Cdk5 / p35. O lanu HEK 293 e faʻaalia ai DRD2-GFP ma Cdk5 / p35 na pisia i anti-Cdk5 ma anti-p35 (Vaega pito i luga). O DRD2-GFP na faʻaalia na o ia i ni manoa faʻapitoa ma faʻamaʻaʻaina i anti-Cdk5 ma anti-p35 (Lower panels). O le Hoechst na faʻaaogaina mo le pipiiina o mea. O le paʻu o le 5 μm. O ata uma na maua e ala i le faʻaogaina o microscopy (Olympus, FluoView-1000).

Pule: 10.1371 / journal.pone.0084482.g003

Cdk5-faʻasalalau Phosphorylation o DRD2 Faʻaauau Avanoa Gaoioiga

Ua lipotia mai o le phosphorylation e faʻapipiʻi ai mea taua o GPCR e pei o le faʻamalosia o le fugatini G, le faʻaogaina o le initaneti, faʻaogaina o le intracellular, ma le faʻatalatalanoaga ma le protein modulate [9], [11], [24]. AO le faʻaaogaina o le initaneti o le faʻaaogaina o le initaneti o se taʻiala faʻapitoa lea o le faʻaliliuga o faʻaliliuga. Sa matou suʻesuʻeina le faʻaogaina o le Cdk5-faʻapitoa i le faʻataʻitaʻiina DRD2 internalization. O lanu HEK 293 e faʻaalia DRD2-GFP ma DRD2 S321A-GFP faʻatasi ma le Cdk5 / p35 na faʻapipiʻiina i le 1 μM quinpirole e faʻaosofia ai le faʻaosoosoina o le DRD2 i totonu o le agonist (Fig. 4A). [3H] -spiperone faailoilo o DRD2-GFP o faʻaalia suauʻu na matuā faʻaitiitia i le 30 min quinpirole togafitiga ma toe maua i le 90 min. Tului, [3H] -spiperone o DRD2-GFP ma Cdk5 / p35 e faʻamalamalama ai suauu na faaitiitia foi i le 30 min quinpirole togafitiga ae le toe maua i 90 min (Fig. 4A, vaega lona lua). Ae o lesi foi itu, [3H] -spiperone signals o DRD2 S321A-GFP o faʻaalia sene na faʻaitiitia i le 30 min ma toe faʻaleleia i le 90 min, e tusa lava po o le a le faʻamatalaina i le Cdk5 / p35. O suʻesuʻega talu ai na faʻaalia ai o le DRD2 internalized ua toe foʻi i tua i le plasma membrane luga o le faʻaosoosoina o agonist [11]. TE foliga mai o le Cdk5-faʻasalalau phosphorylation o DRD2 o loʻo aʻafia i le toe faʻaleleia o gaioiga e mulimuli i le faʻaosoosoina DRD2 internalization.

ata vali

Ata 4. O le Cdk5-faʻapipiʻi phosphorylation e faʻaaogaina le DRD2 ma le faʻaaliga i lalo.

(A) DRD2 faʻaaliga foliga o fuaina e [3H] -spiperone assay binding. O loʻo faʻaaogaina i le 293 μM quinpirole le telefoni o le HEK1 i le taimi faʻatulagaina ma seleseleina, sosoo ai ma le 3 nM [3H] -spiperone togafitiga mo 3 h. Na fua le leitio ma faʻatulagaina faʻailo luga. O pa paʻu e fai ma sui tulaga ± SE (n = 8; * p <0.05, ** p <0.01; Tasi le auala ANOVA ma Dunnett post hoc tofotofoga: faʻatusatusa uma koluma vs. koluma pulea). (B) [35S] -GTPγS o loʻo fusia. O siama siaki na saunia mai suauu na suia e pei ona faʻaalia. Na faʻapipiʻi tapenapenaga o le numera i le 1 μM quinpirole sosoo ai ma le 3 nM [35S] -GTPγS mo le 90 min. Sese pa faʻailoga sui tulaga ± SE (n = 8; * p <0.05, ** p <0.01, *** p <0.001; Tasi le ala ANOVA ma Bonferroni post hoc tofotofoga: faʻatusatusa uma paga o koluma). (C) Quinpirole-tauva [3H] -spiperone assay binding. O sauniuniga mai le suauu ua faʻafesoʻotaʻi na faʻafefiloi ma 0.01 nM [3H] -spiperone ma faʻateleina concentrations o quinpirole mo 30 min. Le maua i lalo laina laina na maua e GraphPad. O faʻailoga o mea sese ua taʻu mai ai le uiga ± SE (n = 3). (D) cAMP enzyme immunoassays i liua HEK 293 sela. O sela na fesuiaʻi na faia i le 10 µM rolipram mo le 1 itula, ma mulimuli ane faia faʻatasi ma le 0.1 µM forskolin ma faʻateleina ai vaega o le quinpirole mo le 30 min. Le maua i lalo laina laina na maua e GraphPad. O paʻu sese e fai ma sui ± ± (n = 4; ** p <0.01; lua-siʻusiʻu t-tese). (E) O togavao faʻasaina mai ituaiga vao ma p35 knockout embryos (DIV 7) na togafitia i le 10 μM rolipram mo 1 h sosoo ai ma 1 μM dopamine mo 1 h. O faʻataʻitaʻiga sese e faʻatusa ai le ± SE (n = 4; **p<0.01; lua-siʻusiʻu t-tese).

Pule: 10.1371 / journal.pone.0084482.g004

Na matou iloiloina atili se suiga talafeagai o le faʻamalosia o le protein G e faʻasaga i le DRD2 e fesoʻotaʻi ma le Cdk5-faʻapipiʻi phosphorylation faʻaaogaina [35S] -GTPγS o loʻo fusia [25], [26]. DRD2-GFP ma DRD2 S321A-GFP faʻatasi ma le leai o Cdk5 / p35 na faʻaalia i le HEK 293 sene. Na saunia ma faʻafeiloaʻi Membranes i le 1 μM quinpirole ma toe faatagaina ai [35S] -GTPγS tuufaatasia. DRD2-GFP ma le Cdk5 / p35 o loʻo faʻaalia ai le paʻu o le cell na faʻaalia le faʻaletonu [35S] -GTPγS mausali pe a faatusatusa i isi isi siama (Fig. 4B). O nei taunuʻuga e iloa ai o le Cdk5-faʻasalalau phosphorylation lalo-e faʻamalosia ai le faʻamalosia o le protein G i DRD2.

E faaopoopo atu i ai, quinpirole-competing [3H] -spiperone binding assays na faia ina ia suʻesuʻeina soʻo se suiga i suiga o le gaioiga i le DRD2 e le Cdk5-faʻapipiʻi phosphorylation. Tausiga malosi o [3H] -pipperone i luga o togafitiga o le faateleina o le mamafa o le uila i le teuteuga o le membrane mai le aafia. Tuufaatasia le fusifusia o quinpirole ma [3H] -spiperone i DRD2-GFP ma DRD2 S321A-GFP na faia se logK tutusai tau (-9.789 mo DRD2-GFP; -9.691 mo DRD2 S321A-GFP), e faailoa mai ai le afaina o le ligand i DRD2 e le aafia tele i le Cdk5-mediated phosphorylation i DRD2 (Fig. 4C).

Cdk5-faʻalogoina Phosphorylation Down-faʻafoe le DRD2-CAMP Faʻamatalaga Ala

I le isi itu, matou te suʻesuʻeina pe o le fesuiaiga o DRD2 e Cdk5 e aʻafia ai auala alafaʻailoga. Sa matou mataituina le DRD2-faʻafeiloaʻiina le faʻasaina o le gaosiga o le CAMP moskolin-adenylyl cyclase i totonu o sel na faʻaalia DRD2-GFP ma DRD2 S321A-GFP faʻaoga immunoassay enzyme CAMP. DRD2-faʻaalia o sel na faʻaalia le faʻaitiitia o maualuga o le CAMP i le tali atu i le quinpirole i se faʻatonuga-faalagolago. O le mea e maofa ai, o le faʻasalaga o le Cdk5 / p35 na faʻaitiitia ai le faʻagataina o le faʻasaina o le faʻavaeina o le CAMP (Fig. 4D, vaega tauagavale). I le isi itu, i le CDD2 S321A-GFP o faʻaalia ai nila, na puipuia lelei le faʻailogaina o le CAMP i le tali atu i togafiti faʻamaʻi e tusa lava pe o le a le Cdk5 / p35 (Fig. 4D, vaega saʻo). O nei taunuuga e faailoa mai ai o le Cdk5-mediated phosphorylation o DRD2 ua tosoina ai le gaoioiga faʻasaʻo a DRD2 i luga ole auala sikuea o le CAMP. Ina ia faʻamaonia atili le tulaga faʻapitoa i se tulaga sili atu o le physiologically, na matou faʻaogaina ai le faʻaaogaina o neu mai le knockout embryos ua le maua i le p35, o le Cdk5 e tatau ona faʻaleleia. O taʻavale faʻapitoa a le Peraimeri na togafitia i 1 μM dopamine ma faʻamaʻiliʻilia e le immunoassay o le enzyme enzyme. Neurons mai le mX35 knockout mice na faʻaalia ai le faʻaitiitia o le maualuga o le CAMP pe a faʻatusatusa i neu neu pe a faʻamalosia i le dopamine (Fig. 4E). TNa matou faʻamaonia, o le Cdk5-faʻasalalau phosphorylation o DRD2 o loʻo faʻaalia ai le faʻaitiitia o le leo faʻasaina i luga o le auala a le CAMP o loʻo faʻatinoina e DRD2.

Talanoaga

Na matou faailoa DRD2 e avea o se mea fou o le Cdk5. O le foliga mai o le phosphorylation o loʻo faʻapipiʻiina ai DRD2 faʻaaliga ile foliga e aʻafia ai le faʻalavelave o DRD2 mulimuli mai le internatist internalization ma faʻaitiitia ai le DRD2 Gi-solo ma ala i lalo o le auala CAMP. A o le S321 o le phosphorylation o loʻo i DRD2 umi ma le vaʻaia, o le masini na faʻatulagaina i lenei suʻesuʻega atonu o se tulaga lautele o tulafono faatonutonu i le DRD2-faʻaaliga faʻamaonia.

DRD2 i le vavao vavalaʻau laʻititi e le gata o loʻo avea o se subtype autu o le responsor dopamine ae ua amanaʻia foi ona o lona faʻafesoʻotaʻi i suiga i le avanoa e tali atu ai i le faʻaleleia o le siosiomaga. O le faʻaaogaina o le tino o le DRD2 ma le toe faʻamautuina o le DRDXNUMX ua maeʻa suʻesuʻeina [11], [24]. Aemaise lava, o le tele o suʻesuʻega ua faaalia ai o aafiaga o le soifua maloloina o le psychostimulant, e pei o le cocaine ma le amphetamine, lea e siitia ai le extracellular o le dopamine i le synapse tetele, eo faatasi ma suiga malosi o DRD2 postsynaptically [36]. O le mea moni, e masani ona iloa e tagata faʻaogaina o le cocaine le faʻaitiitia o RDD2 i le vaega tele, ma le DRD2 o loʻo maua i le nucleus accumbens (NAcc) e faʻaalia ai se faʻasalaga le lelei ma le faʻataʻitaʻiga ma le faʻamalosia o amioga i mumusu ma primates [37]-[39]. O nei suʻesuʻega ua faailoa mai ai o le tulaga o le DRD2 e sili ona faʻaogaina i tulafono faatonutonu faʻapitoa poʻo le faʻasalaga e tali atu ai i faʻalavelave faʻapitoa e aofia ai faʻamaʻi masani faʻafefe. O a matou taunuʻuga o loʻo faʻaalia ai o le S321 o totoe i le tolu o le intracellular loop of DRD2 e mafai ona phosphorylated e le Cdk5, lea e mafua ai le faʻaitiitia o le faʻatoʻilaloina o DRD2 i luga o le auala CAMP. O lenei fegalegaleaiga ua fuafua ai se faiga faʻavae taʻiala e fesoʻotaʻi ma le Cdk5 i nepone dopaminoceptive e mafai ona fesoʻotaʻi atu i le uiga malosi o DRD2 o loʻo avanoa.

E tatau ona maitauina o le Cdk5 ua lauiloa o se vaega autū i le faʻasalalau suiga o suiga o le siosiomaga o le neuronal. Mo se faʻataʻitaʻiga, o suiga faʻavae ma faʻatinoga o vailaʻau o le dendritic i le neurons o le eletise limbicide o se tasi o taunuuga o le faʻaalia pea o le psychostimulant exposure [40]. O nei suiga e ogatasi ma suiga eseese o le mole mole suiga e aofia ai le faʻaofiina o le palemene e tali mai ai le CAMP-fusi (CREB) ma le ΔFosB, faʻamaumauga o faʻamatalaga e faʻaalia ai se tulafono faatonutonu tumau i le tali atu i le pulega o cocaine masani [41], [42]. O le mea sili ona taua, o le Cdk5 o se taulaiga o le ΔFosB [19], ma le tele o vaega taua o loʻo aʻafia ai i vailaʻau o le viliina o le dendritic, pei o PSD-95, p21-activated kinase (PAK), β-catenin, ma le spinophilin, na lipotia mai o substitute Cdk5 [43]-[46]. O le faʻaauau pea, togafiti poʻo le faʻaaogaina o vailaʻau faʻataʻitaʻiga o le Cdk5 gaoioiga e faʻaalia ai suiga o le vailaau o le vailaʻau o le dendritic ma tali a amioga i cocaine, e taua ai le taua o matafaioi mo le Cdk5 i suiga mole mole ma morphology o mesolimbic dopamine circuits [47], [48]. O a matou taunuʻuga e faʻaalia ai DRD2 o se faʻataʻitaʻiga autu o le Cdk5 o loʻo maua ai se malamalamaga faʻaopopo i fetuunaiga talafeagai o le polokalama o le dopamine e tali atu i faʻataʻitaʻiga faʻasalalau faʻasalalau ona o le mulimuli ane o tulafono faatonutonu a le Cdk5 e mafai ona faatupuina le maualuga o le phosphorylation o DRD2 . E le gata i lea, ua iloa DRD2 e aʻafia ai le tele o telefoni feaveaʻi, e aofia ai tulafono faatonutonu o le CAMP ma le MAP kinase ala ma mea i lalo [42], [49]. O le mea lea, o sailiga i lenei suʻesuʻega atonu e le gata ina faʻataʻitaʻiina ai se tulafono faatonutonu tuusao a DRD2 e Cdk5 ae faʻapea foi ona tuʻuina atu ai se faʻamatalaga malamalama i tali talafeagai a le komini o le dopamine i le faʻateleina o fualaau faasaina.

Tusitala Tusitala

Faʻatinoina ma fuafuaina fuafuaga faʻapitoa: JJ YUP DH SKP. Faia suʻega: JJ YUP DKK YK. Iloilo faamatalaga: JJ YUP DKK SL YK SAL HL YSG DH SKP. Mea na tuʻufaʻatasia / mea faʻapipiʻi / auiliiliga: YHS. Ave le pepa: JJ SKP.

mau faasino

  1. 1. Misasle C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine rescepters: mai le fausaga e galue ai. Physiol Rev 78: 189-225.
  2. 2. Sini Atamai RA (2002) Faʻasalalau taui o Brain: malamalamaaga mai mea e le faʻasaoina. Neuron 36: 229-240. i: 10.1016 / s0896-6273 (02) 00965-0
  3. Faʻaaliga Mataupu
  4. PubMed / NCBI
  5. Scholar Google
  6. Faʻaaliga Mataupu
  7. PubMed / NCBI
  8. Scholar Google
  9. Faʻaaliga Mataupu
  10. PubMed / NCBI
  11. Scholar Google
  12. Faʻaaliga Mataupu
  13. PubMed / NCBI
  14. Scholar Google
  15. Faʻaaliga Mataupu
  16. PubMed / NCBI
  17. Scholar Google
  18. Faʻaaliga Mataupu
  19. PubMed / NCBI
  20. Scholar Google
  21. Faʻaaliga Mataupu
  22. PubMed / NCBI
  23. Scholar Google
  24. Faʻaaliga Mataupu
  25. PubMed / NCBI
  26. Scholar Google
  27. Faʻaaliga Mataupu
  28. PubMed / NCBI
  29. Scholar Google
  30. Faʻaaliga Mataupu
  31. PubMed / NCBI
  32. Scholar Google
  33. Faʻaaliga Mataupu
  34. PubMed / NCBI
  35. Scholar Google
  36. Faʻaaliga Mataupu
  37. PubMed / NCBI
  38. Scholar Google
  39. Faʻaaliga Mataupu
  40. PubMed / NCBI
  41. Scholar Google
  42. Faʻaaliga Mataupu
  43. PubMed / NCBI
  44. Scholar Google
  45. Faʻaaliga Mataupu
  46. PubMed / NCBI
  47. Scholar Google
  48. Faʻaaliga Mataupu
  49. PubMed / NCBI
  50. Scholar Google
  51. Faʻaaliga Mataupu
  52. PubMed / NCBI
  53. Scholar Google
  54. Faʻaaliga Mataupu
  55. PubMed / NCBI
  56. Scholar Google
  57. Faʻaaliga Mataupu
  58. PubMed / NCBI
  59. Scholar Google
  60. Faʻaaliga Mataupu
  61. PubMed / NCBI
  62. Scholar Google
  63. Faʻaaliga Mataupu
  64. PubMed / NCBI
  65. Scholar Google
  66. Faʻaaliga Mataupu
  67. PubMed / NCBI
  68. Scholar Google
  69. Faʻaaliga Mataupu
  70. PubMed / NCBI
  71. Scholar Google
  72. Faʻaaliga Mataupu
  73. PubMed / NCBI
  74. Scholar Google
  75. Faʻaaliga Mataupu
  76. PubMed / NCBI
  77. Scholar Google
  78. Faʻaaliga Mataupu
  79. PubMed / NCBI
  80. Scholar Google
  81. Faʻaaliga Mataupu
  82. PubMed / NCBI
  83. Scholar Google
  84. Faʻaaliga Mataupu
  85. PubMed / NCBI
  86. Scholar Google
  87. Faʻaaliga Mataupu
  88. PubMed / NCBI
  89. Scholar Google
  90. Faʻaaliga Mataupu
  91. PubMed / NCBI
  92. Scholar Google
  93. Faʻaaliga Mataupu
  94. PubMed / NCBI
  95. Scholar Google
  96. Faʻaaliga Mataupu
  97. PubMed / NCBI
  98. Scholar Google
  99. Faʻaaliga Mataupu
  100. PubMed / NCBI
  101. Scholar Google
  102. Faʻaaliga Mataupu
  103. PubMed / NCBI
  104. Scholar Google
  105. Faʻaaliga Mataupu
  106. PubMed / NCBI
  107. Scholar Google
  108. Faʻaaliga Mataupu
  109. PubMed / NCBI
  110. Scholar Google
  111. Faʻaaliga Mataupu
  112. PubMed / NCBI
  113. Scholar Google
  114. Faʻaaliga Mataupu
  115. PubMed / NCBI
  116. Scholar Google
  117. Faʻaaliga Mataupu
  118. PubMed / NCBI
  119. Scholar Google
  120. Faʻaaliga Mataupu
  121. PubMed / NCBI
  122. Scholar Google
  123. Faʻaaliga Mataupu
  124. PubMed / NCBI
  125. Scholar Google
  126. Faʻaaliga Mataupu
  127. PubMed / NCBI
  128. Scholar Google
  129. Faʻaaliga Mataupu
  130. PubMed / NCBI
  131. Scholar Google
  132. Faʻaaliga Mataupu
  133. PubMed / NCBI
  134. Scholar Google
  135. Faʻaaliga Mataupu
  136. PubMed / NCBI
  137. Scholar Google
  138. Faʻaaliga Mataupu
  139. PubMed / NCBI
  140. Scholar Google
  141. Faʻaaliga Mataupu
  142. PubMed / NCBI
  143. Scholar Google
  144. 3. Neve KA, Seamans JK, Trantham-Davidson H (2004) Faʻailoga o le talipupuni o le Dopamine. J Faʻafeiloaʻi Faʻamaumauga o Faʻamaumauga 24: 165-205. doi: 10.1081 / lrst-200029981
  145. 4. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, et al. (2008) Faʻatonuina o le faʻaaogaina o moli faaiu o le senitonu D2 i le pathophiosiology o le schizophrenia. Int J Neuropsychopharmacol 11: 197-205. Pule: 10.1017 / s1461145707007948
  146. 5. Caine SB, Negus SS, Mello NK, Patel S, Bristow L, et al. (2002) Matafaioi o le resamine o le dopamine D2 pei o le cocaine: suʻesuʻega ma muti mutant mutant D2 ma le tusitala D2 faʻataʻitaʻi. J Neurosci 22: 2977-2988.
  147. 6. Lee S, Jeong J, Park YU, Kwak Y, Lee SA, et al. (2012) Valproate alters dopamine faʻamaufaʻailogaina i le fesoʻotaʻiga ma le induction o le faʻamatalaga o le protein o le Par-4. PLoS Tasi le 7: e45618. doi: 10.1371 / journal.pone.0045618
  148. 7. Fishburn CS, Elazar Z, Fuchs S (1995) Eseesega o le glycosylation ma fefaatauaiga intracellular mo le umi ma le puupuu o le tulaga o le D2 dopamine receptor. J Biol Chem 270: 29819-29824. Pule: 10.1074 / jbc.270.50.29819
  149. 8. Taʻitaʻi TA TA, Molina-Holgado E, Lima L, Boulianne S, Dewar KM (1992) Lapataiga [3H] raclopride e fusifusia i le neostriatal dopamine D2 faʻaaliga: o le vaega o disulfide ma vaega sulfhydryl. Neurochem Res 17: 749-759. Tui: 10.1007 / bf00969008
  150. 9. Ng GY, O'Dowd BF, Caron M, Dennis M, Brann MR, et al. (1994) Phosphorylation ma le palmitoylation o le tagata D2L dopamine receptor i Sf9 sene. J Neurochem 63: 1589-1595. Pule: 10.1046 / j.1471-4159.1994.63051589.x
  151. 10. Li M, Bermak JC, Wang ZW, Zhou QY (2000) Faʻaaogāina o le dopamine D (2) faʻamaufaʻailogaina e ala i le fusi faʻamauina (ACTP-280). Mol Pharmacol 57: 446-452.
  152. 11. Cho D, Zheng M, Min C, Ma L, Kurose H, et al. (2010) O le endocytosis-induced-induced-agonist ma le receptor phosphorylation e faʻatautaia ai le toe faʻafouina o le numera o dopamine D (2). Mol Endocrinol 24: 574-586. doi: 10.1210 / me.2009-0369
  153. 12. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E (1994) p35 o se vaega o le tulafono faatonutonu faapitoa o le 5 fatuina o le cyclin-dependent. Natura 371: 419-423. doi: 10.1038 / 371419A0
  154. 13. Dhavan R, Tsai LH (2001) Se sefulu tausaga o CDK5. Nat Rev Mol Cell Biol 2: 749-759. Pule: 10.1038 / 35096019
  155. 14. Fu AK, Ip NY (2007) 5 fatuina o le Cyclin-toto e fesoʻotaʻi atu i faʻamatalaga extracellular e fai ai le cytoskeleton i le taimi o le atinaeina o le vavalaʻau dendritic. Cell Adh Migr 1: 110-112. Pule: 10.4161 / cam.1.2.4617
  156. 15. O Wang J, Liu S, Fu Y, Wang JH, Lu Y (2003) Cdk5 faʻamalosiaga na mafua ai le maliu o le CA1 i le hippocampal e ala i le faʻafesoʻotaʻi saʻo atu o le NMDA. Nat Neurosci 6: 1039-1047. doi: 10.1038 / nn1119
  157. 16. Zhang S, Edelmann L, Liu J, Crandall JE, Morabito MA (2008) Cdk5 e faatonutonu ai le phosphorylation o tyrosine 1472 NR2B ma le faʻaaliga o le NMDA. J Neurosci 28: 415-424. doi: 10.1523 / jneurosci.1900-07.2008
  158. 17. Moy LY, Tsai LH (2004) 5 phosphorylates 31 o le tyrosine hydroxylase ma faʻasolosolo ai lona mausali. J Biol Chem 279: 54487-54493. doi: 10.1074 / jbc.m406636200
  159. 18. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, et al. (1999) Phosphorylation o le DARPP-32 e Cdk5 e faʻafeiloaʻi ai le dopamine i totonu o laina. Natura 402: 669-671.
  160. 19. Bibb JA, Chen J, Taylor JR, Svenningsson P, Nishi A, et al. (2001) O aʻafiaga e masani ona faʻaalia ile cocaine e faʻatulafonoina e le protein neuronal Cdk5. Natura 410: 376-380.
  161. 20. Ohshima T, Ogawa M, Veeranna, Hirasawa M, Longenecker G, et al. (2001) Fesoasoaniga a le 5 / p35 ma le Reelin / Dab1 aʻafiaga o le cyclin i le faʻatulagaina o neu o le cortical i le atinaʻeina o le fatu. Faʻaalia Natl Acad Sci USA 98: 2764-2769. doi: 10.1073 / pnas.051628498
  162. 21. Morabito MA, Sheng M, Tsai LH (2004) 5 fatuina o le Cyclin-95 phosphorylaina le vaega N-faʻamalosi o le PSD-24 proteous density postlnaptic i neurons. J Neurosci 865: 876-10.1523. doi: 4582 / jneurosci.03.2004-XNUMX
  163. 22. Park SK, Nguyen MD, Fischer A, MP MP, Affar el B, et al. (2005) Par-4 fesoʻotaʻiga faailoilo dopamine ma le atuatuvale. Cell 122: 275-287. Pule: 10.1016 / j.cell.2005.05.031
  164. 23. Niethammer M, Smith DS, Ayala R, Peng J, Ko J, et al. (2000) NUDEL o se tusiga Cdk5 o loʻo fesoʻotaʻi ma le LIS1 ma le cytoplasmic dynein. Neuron 28: 697-711. i: 10.1016 / s0896-6273 (00) 00147-1
  165. 24. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, et al. (2001) Faʻasalalauga eseʻese o le dopamine D2 ma le D3 faʻataʻitaʻiga e le G faʻamaʻi faʻamaʻi faʻamaʻi ma le beta-arrestins. J Biol Chem 276: 37409-37414. doi: 10.1074 / jbc.m106728200
  166. 25. Waldhoer M, Bofill-Cardona E, Milligan G, Freissmuth M, Nanoff C (1998) Eseesega o le faʻaogaina o le A1 adenosine ma le D2 dopamine receptors e suramin ma le Rosemethylated suramin (NF037). Mol Pharmacol 53: 808-818.
  167. 26. Bofill-Cardona E, Kudiaok O, Yang Q, Ahorn H, Freissmuth M, et al. (2000) O le faʻalagolago i le calmodulin i le D2-dopamine receptor e faʻaitiitia ai le faʻamaoniga o le initaneti e ala i le puʻeina o le G-activation switch activation. J Biol Chem 275: 32672-32680. doi: 10.1074 / jbc.m002780200
  168. 27. Lisi SJ, Seeman P (1981) Filifiliga o le dopamine ma le serotonin vaega o le [3H] spiperone e fusifusia i le vaʻai o le brain brain. Faʻaalia Natl Acad Sci USA 78: 2620-2624. doi: 10.1073 / pnas.78.4.2620
  169. 28. Gardner B, Eseesega PG (1998) Agonist i le D2 (umi) tali o le dopamine: ligand bond and assays assays. Br J Pharmacol 124: 978-984. doi: 10.1038 / sj.bjp.0701926
  170. 29. Seeman P, Tallerico T, Ko F (2003) Dopamine e toesea le [3H] domperidone mai nofoaga maualuga o le afaina o le dopamine D2, ae le o le [3H] raclopride poo le [3H] spiperone i le isotonic medium: O aʻafiaga mo le initaneti o le positron emissiongraphy. Synapse 49: 209-215. doi: 10.1002 / syn.10232
  171. 30. Obenauer JC, Cantley LC, Yaffe MB (2003) Faʻasalalau 2.0: Vaʻaiga faʻasaʻo lautele o fesoʻotaʻiga faʻamaonia cell e faʻaaoga ai faʻasologa o le faasologa puupuu. Nucleic Acids Res 31: 3635-3641. doi: 10.1093 / nar / gkg584
  172. 31. Liu H, Sadygov RG, Yates JR 3rd (2004) O se faʻataʻitaʻiga mo le faʻataʻitaʻiina o fuainumera ma le faʻatusatusaina o le tele o le protein i le puipuia o fana. Anal Chem 76: 4193-4201. doi: 10.1021 / ac0498563
  173. 32. Ito K, Haga T, Lameh J, Sadee W (1999) O le faʻaaogaina o le dopamine D2 e faʻalagolago i le faʻaalia o le G-protein-coupled kincy kinases 2 poʻo le 5. Eur J Biochem 260: 112-119. Pule: 10.1046 / j.1432-1327.1999.00125.x
  174. 33. Namkung Y, Sibley DR (2004) Protein kinase C mediates phosphorylation, faʻaaogaina, ma fefaʻatauaiga o le D2 dopamine receptor. J Biol Chem 279: 49533-49541. doi: 10.1074 / jbc.m408319200
  175. 34. Wong AS, Lee RH, Cheung AY, Yeung PK, Chung SK, et al. (2011) Cdk5-faʻasalalau phosphorylation o le B1 faʻasalaga e manaʻomia mo le faʻamalosia o le autophagy i faʻataʻitaʻiga o le maʻi o Parkinson. Nat Cell Biol 13: 568-579. Pule: 10.1038 / ncb2217
  176. 35. Kesavapany S, Lau KF, McLoughlin DM, Brownlees J, Ackerley S, et al. (2001) p35 / cdk5 fusifusia ma phosphorylates beta-catenin ma faʻatonutonu ai fesootaiga beta-catenin / presenilin-1. Eur J Neurosci 13: 241-247. Pule: 10.1046 / j.1460-9568.2001.01376.x
  177. 36. Kuhar MJ, Ritz MC, Boja JW (1991) O le manatu o le dopamine o le faʻamalosia o meatotino o cocaine. Trends Neurosci 14: 299-302. doi: 10.1016 / 0166-2236 (91) 90141-g
  178. 37. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, et al. (1990) Aafiaga o le faʻaleagaina o le cocaine masani i luga o le postsynaptic o le talini. Am J Psychiatry 147: 719-724.
  179. 38. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, et al. (2007) Nucleus accumbens D2 / 3 suʻega e vaʻaia le le mautonu o le amio ma le faʻamalosia o cocaine. Saienisi 315: 1267-1270. doi: 10.1126 / science.1137073
  180. 39. Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, et al. (2006) PET faʻataʻitaʻiga o le numera o le senate o le dopamine D2 i taimi o aʻoga masani i cocaine i manuki. Nat Neurosci 9: 1050-1056. doi: 10.1038 / nn1737
  181. 40. Robinson TE, Kolb B (1997) Faʻaauau pea le faʻaleleia o fausaga i ulutala accumbens ma le muamua o le cortex neurons na maua mai i aafiaga muamua ma le amphetamine. J Neurosci 17: 8491-8497.
  182. 41. Robinson TE, Kolb B (1999) Suiga i le faʻaogaina o dendrites ma vailaʻau o le dendritic i totonu o le tumutumu o le accumbens ma le muamua o le cortex e mulimuli i togafitiga faifaipea ma le amphetamine poʻo le cocaine. Eur J Neurosci 11: 1598-1604. Pule: 10.1046 / j.1460-9568.1999.00576.x
  183. 42. McClung CA, Nestler EJ (2003) Faʻataʻitaʻiga o le faʻaalia o le faʻamaʻi ma le cocaine e le CREB ma le DeltaFosB. Nat Neurosci 6: 1208-1215. doi: 10.1038 / nn1143
  184. 43. Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, et al. (2000) Spinophilin faʻafoe le faʻatulagaina ma le gaioiga o vailaʻau dendritic. Faʻaalia Natl Acad Sci USA 97: 9287-9292. doi: 10.1073 / pnas.97.16.9287
  185. 44. Prange O, Murphy TH (2001) Faʻaleleia faʻapitoa o le postsynaptic density-95 fluso ma fegalegaleaiga ma vailaʻau faʻasaina i le amataga o le atinaʻeina o neu. J Neurosci 21: 9325-9333.
  186. 45. Murase S, Mosser E, Schuman EM (2002) Faʻatinoina o le beta-Catenin i vavao faʻasolosolo e faʻaleleia ai suiga i le faʻasologa ma le faʻatulagaina o synaptic. Neuron 35: 91-105. doi: 10.1016 / s0896-6273 (02) 00764-x
  187. 46. Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, et al. (2004) Faʻaliliuga o le faʻaogaina o mea faʻapitoa mo le faʻamalosia o le mafaufau ma le faʻamalosia o le faʻamalosia o le mafaufau i le muaʻi vaʻaia-o le mea e sili ona taua-le lelei le PAK transivesic souris. Neuron 42: 773-787. Pule: 10.1016 / j.neuron.2004.05.003
  188. 47. Benavides DR, Quinn JJ, Zhong P, Hawasli AH, DiLeone RJ, et al. (2007) Cdk5 faʻafetaui le taui o cocaine, faaosofiaga, ma le malosi o le neuron. J Neurosci 27: 12967-12976. doi: 10.1523 / jneurosci.4061-07.2007
  189. 48. Meyer DA, Richer E, Benkovic SA, Hayashi K, Kansy JW, et al. (2008) Faʻasalalauga a le Cdk5 i tali o le locomotor i le cocaine, aʻoaʻoga a le moa, ma le vailaʻau o le dendritic. Faʻaalia Natl Acad Sci USA 105: 18561-18566. doi: 10.1073 / pnas.0806078105
  190. 49. Impey S, Obrietan K, Storm DR (1999) Fai fesootaiga fou: matafaioi a le ERK / MAP kinase o loʻo faʻaalia i le neuronal plasticity. Neuron 23: 11-14. i: 10.1016 / s0896-6273 (00) 80747-3